Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 7/2018

01-07-2018 | Letter to the Editor

Histological transformation of MALT lymphoma to plasma cell leukemia after rituximab-containing therapy

Authors: Yutaro Suzuki, Akira Honda, Kumi Nakazaki, Hideaki Mizuno, Masako Ikemura, Aya Shinozaki-Ushiku, Fumihiko Nakamura, Masashi Fukayama, Mineo Kurokawa

Published in: Annals of Hematology | Issue 7/2018

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Wöhrer S, Troch M, Streubel B, Hoffmann M, Müllauer L, Chott A et al (2007) Pathology and clinical course of MALT lymphoma with plasmacytic differentiation. Ann Oncol 18(12):2020–2024CrossRefPubMed
2.
Cohen SM, Petryk M, Varma M, Kozuch PS, Ames ED, Grossbard ML (2006) Non-Hodgkin’s lymphoma of mucosa-associated lymphoid tissue. Lymphoma Oncol Oncol 1111:1100–1117
3.
Tsukamoto A, Nakamura F, Nannya Y, Kobayashi Y, Shibahara J, Ichikawa M, Fukayama M, Koike K, Kurokawa M (2014) MALT lymphoma of the small bowel with protein-losing enteropathy. Int J Hematol 99:198–201CrossRefPubMed
4.
Nakamura F, Nakamura F, Ikemura M, Fukayama M, Kurokawa M (2016) Extraosseous plasmacytoma in the nasal cavity after rituximab therapy against pulmonary MALT lymphoma. Ann Hematol 95:1733–1735CrossRefPubMed
5.
Woehrer S, Streubel B, Chott A, Hoffmann M, Raderer M (2005) Transformation of MALT lymphoma to pure plasma cell histology following treatment with the anti-CD20 antibody rituximab. Leuk Lymphoma 46(11):1645–1649CrossRefPubMed
6.
Klein N, Elis A, Radnay J, Zemer R, Klein A, Lishner M (2009) Transformation of MALT lymphoma to pure plasma cell histology: possible association with anti-CD20 antibody treatment. Isr Med Assoc J 11:703–704PubMed
Metadata
Title
Histological transformation of MALT lymphoma to plasma cell leukemia after rituximab-containing therapy
Authors
Yutaro Suzuki
Akira Honda
Kumi Nakazaki
Hideaki Mizuno
Masako Ikemura
Aya Shinozaki-Ushiku
Fumihiko Nakamura
Masashi Fukayama
Mineo Kurokawa
Publication date
01-07-2018
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 7/2018
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-018-3300-2

Other articles of this Issue 7/2018

Annals of Hematology 7/2018 Go to the issue

Original Article

Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant

Original Article

Consensus statement for cancer patients requiring intensive care support

Review Article

Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review

Original Article

Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia

Original Article

Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia

Original Article

Elevated expression of the EZH2 gene in CALR-mutated patients with primary myelofibrosis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits